Literature DB >> 16353205

Classic Kaposi sarcoma. Which KSHV-seropositive individuals are at risk?

Emma Guttman-Yassky1, Jonathan Dubnov, Zippi Kra-Oz, Rachel Friedman-Birnbaum, Michael Silbermann, Micha Barchana, Reuven Bergman, Ronit Sarid.   

Abstract

BACKGROUND: Classic Kaposi sarcoma (CKS) is a relatively rare vascular disease primarily affecting human immunodeficiency virus (HIV)-uninfected elderly men. The infection with Kaposi sarcoma-associated herpesvirus (KSHV) is necessary for the establishment of Kaposi sarcoma (KS), although it is not sufficient. Thus, only a small fraction of KSHV-infected individuals develops KS. The cofactors that influence risk of KS among HIV-uninfected individuals are yet to be determined. The objective of the current study was to assess potential risk factors for CKS in the KSHV-infected Jewish population in Israel.
METHODS: A case-control study involved 35 CKS cases and 48 matched KSHV-infected controls. Lifestyle and medical history data from case patients and controls were compared by logistic regression analysis.
RESULTS: In a multivariate analysis, the authors identified an age-related small increased risk for CKS in subjects originating from Asia and Africa. The risk for CKS increased, although not significantly statistically, in subjects who reported alcohol consumption, diabetes mellitus, herpes simplex, and asthma. No relation was found with cigarette smoking, family size, number of lifetime sexual partners, or sexually transmitted disease.
CONCLUSIONS: A borderline increase in CKS risk among elderly subjects originating from Africa or Asia was identified. These results need to be further evaluated by larger studies. The authors believe that genetic and immunologic parameters may alter risk for CKS and, therefore, should also be investigated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353205     DOI: 10.1002/cncr.21614

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Targeted therapy for Kaposi sarcoma.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Bruce J Dezube
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

2.  Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily.

Authors:  Lesley A Anderson; Carmela Lauria; Nino Romano; Elizabeth E Brown; Denise Whitby; Barry I Graubard; Yan Li; Angelo Messina; Lorenzo Gafà; Francesco Vitale; James J Goedert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

3.  Predictors of seropositivity for human herpesvirus type 8 in patients with mild cirrhosis.

Authors:  Kuo-Chih Tseng; Ming-Nan Lin; Tang-Yuan Chu; Jen-Pi Tsai; Cheng-Chuan Su
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

4.  Diabetes and risk of Kaposi's sarcoma: effects of high glucose on reactivation and infection of Kaposi's sarcoma-associated herpesvirus.

Authors:  Pey-Jium Chang; Yao-Hsu Yang; Pau-Chung Chen; Lee-Wen Chen; Shie-Shan Wang; Ying-Ju Shih; Li-Yu Chen; Chi-Jen Chen; Chien-Hui Hung; Chun-Liang Lin
Journal:  Oncotarget       Date:  2017-07-28

5.  Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement.

Authors:  Giuseppe Badalamenti; Lorena Incorvaia; Laura Algeri; Annalisa Bonasera; Alessandra Dimino; Raimondo Scalia; Alessandra Cucinella; Giorgio Madonia; Federica Li Pomi; Antonio Galvano; Valerio Gristina; Francesca Toia; Adriana Cordova; Viviana Bazan; Antonio Russo
Journal:  Ther Adv Med Oncol       Date:  2022-03-26       Impact factor: 8.168

6.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.